Back to top
more

Cigna Group (CI)

(Delayed Data from NYSE)

$358.58 USD

358.58
970,346

+9.74 (2.79%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $358.57 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 6% (236 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

UnitedHealth Q3 Earnings Beat on Domestic Commercial Business

by Zacks Equity Research

UNH's third-quarter earnings benefit on the back of client wins in the Optum Rx sub-unit, partly offset by an elevated operating expense level.

Elevance's Pre-Q3 Earnings Analysis: Smart Buy Now or Caution Ahead?

by Zacks Equity Research

ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.

Why Cigna (CI) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Urmimala Biswas headshot

CVS Stock Hits 50-Day SMA on Split Rumors: How Should You Play?

by Urmimala Biswas

The market speculates that following the FTC notice, several investors are pushing CVS Health to go for segment breakups.

Here's Why Cigna (CI) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Kaibalya Pravo Dey headshot

UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?

by Kaibalya Pravo Dey

With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.

Cigna's Health Benefits Unit Launches a New E-Treatment Option

by Zacks Equity Research

CI's new launch, a new E-Treatment option, is expected to improve patient satisfaction and operational efficiency.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

by Zacks Equity Research

CI benefits from improved premiums resulting from an extensive customer base. Buyouts and adequate operating cash flows are other tailwinds.

Why Cigna (CI) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cigna (CI) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Encompass Health (EHC) Stock Down 6% Despite Q2 Earnings Beat

by Zacks Equity Research

Encompass Health's (EHC) Q2 results reflect improved net patient revenue per discharge, partly offset by higher costs. It currently estimates 2024 adjusted EPS within $3.97-$4.22, up from the earlier view of $3.86-$4.11.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

Cigna (CI) Q2 Earnings Top on Specialty Business Strength

by Zacks Equity Research

Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.

Cigna (CI) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cigna (CI) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cigna (CI) delivered earnings and revenue surprises of 4.67% and 3.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Cigna (CI) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Humana (HUM) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 18.17% and 2.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

by Zacks Equity Research

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.